肺癌免疫疗法概述。
Overview of Lung Cancer Immunotherapy.
机构信息
From the Program of Immunology and Immunotherapy, Center for Applied Medical Research.
Department of Pathology, Yale University School of Medicine, New Haven, CT.
出版信息
Cancer J. 2020 Nov/Dec;26(6):473-484. doi: 10.1097/PPO.0000000000000488.
Anti-PD-(L)1 therapy represents a turning point in lung cancer immunotherapy, moving from previously ineffective enhancer strategies to immune checkpoints as standard first- and second-line therapies. This unprecedented success highlights the importance of mechanisms to escape immune attack, such PD-1/PD-L1 axis, and emphasize the importance to better understand the tumor immune microenvironment. Analyzing the specifics of immune response against lung tumor cells and how malignant cells progressively adapt to this pressure may help to understand which are the key aspects to guide the development of new therapeutic strategies. Here we review the past and present of clinical lung cancer immunotherapy and give a perspective for the future development based on emerging biological insights.
抗 PD-(L)1 治疗代表了肺癌免疫治疗的一个转折点，从以前无效的增强策略转向免疫检查点作为标准的一线和二线治疗。这一前所未有的成功突显了逃避免疫攻击的机制的重要性，如 PD-1/PD-L1 轴，并强调了更好地了解肿瘤免疫微环境的重要性。分析针对肺癌肿瘤细胞的免疫反应的具体情况以及恶性细胞如何逐渐适应这种压力，可能有助于了解哪些是指导新治疗策略发展的关键方面。在这里，我们回顾了临床肺癌免疫治疗的过去和现在，并基于新兴的生物学见解展望了未来的发展方向。
Zotero 插件